Johnson & Johnson’s $572 million opioid verdict in Oklahoma made headlines this summer, but the company’s lawyers quickly sought to reduce the figure. Now, the judge has slashed the verdict to $465 million to cover one year of crisis abatement,
read morePHILADELPHIA—With an FDA decision to expand Amarin’s Vascepa label to include cardiovascular risk reduction looming, a new imaging study shows the drug could have an effect on stopping the progression of plaque in the arteries. That could help explain Vascepa’s
read moreThe funding announcement coincides with the launch of Cancer Research UK’s “Right Now” campaign, which aims to show both the realities of the disease and the positive impact research and improved treatments can have on people’s lives. More: £373k awarded
read moreAs of the approval, the treatment is expected to be available to patients in the coming weeks. More: Adakveo bags FDA approval for sickle cell pain Source: News
read moreThe trial is the first with an SGLT2 inhibitor investigating the treatment of heart failure in patients with reduced ejection fraction, with and without type II diabetes. More: Farxiga demonstrates consistent heart failure benefits in late-stage trial Source: News
read moreThe industry body hopes that the proceeding Government will “shape one of our country’s most valuable assets: an incredible pharmaceutical industry that employs tens of thousands and invests billions in research.” More: ABPI launches general election manifesto Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals